Healthcare Equipment and Supplies
Company Overview of REVA Medical, Inc.
REVA Medical, Inc., a development stage medical device company, focuses on the commercialization of minimally invasive medical devices for the treatment of coronary artery disease in the human heart. It is developing and testing a bioresorbable stent to treat vascular disease in humans under the Fantom scaffolds name. The company was formerly known as MD3, Inc. and changed its name to REVA Medical, Inc. in March 2002. REVA Medical, Inc. was founded in 1998 and is headquartered in San Diego, California.
5751 Copley Drive
San Diego, CA 92111
Founded in 1998
Key Executives for REVA Medical, Inc.
Co-founder, Chairman and Chief Executive Officer
Total Annual Compensation: $359.7K
President and Chief Operating Officer
Total Annual Compensation: $340.8K
Chief Financial Officer and Company Secretary
Total Annual Compensation: $275.2K
Senior Vice President of Clinical and Regulatory Affairs
Total Annual Compensation: $260.9K
Senior Vice President of Product Development
Total Annual Compensation: $254.0K
Compensation as of Fiscal Year 2013.
REVA Medical, Inc. Key Developments
REVA Medical, Inc. Reports Audited Consolidated Earnings Results for the Full Year Ended December 31, 2014
Mar 30 15
REVA Medical, Inc. reported audited consolidated earnings results for the full year ended December 31, 2014. For the year, the company reported loss from operations of $21,963,000 compared to loss from operations of $27,943,000 for the same period a year ago. Net loss and comprehensive loss was $51,037,000 or $1.53 per basic and diluted share compared to $27,922,000 or $0.84 per basic and diluted share last year. Net cash used for operating activities was $17,930,000 compared to $21,943,000 last year. Purchases of property and equipment were $541,000 compared to $1,466,000 last year.
REVA Medical, Inc. Appoints Scott Huennekens as Non-Executive Director
Mar 25 15
REVA Medical, Inc. announced that Scott Huennekens, a recognized business executive in the medical device industry, has been appointed to its Board of Directors as a non-executive director. Mr. Huennekens currently serves on the boards of EndoChoice, Sonendo, Scripps Translational Science Institute, and the Medical Device Manufacturers Association (MDMA).
REVA Medical, Inc. Announces the Initiation of Patient Enrollment in the FANTOM II Clinical Trial of its Fantom™ Sirolimus-eluting bioresorbable scaffold
Mar 16 15
REVA Medical, Inc. announced the initiation of patient enrollment in the FANTOM II clinical trial of its Fantom™ sirolimus-eluting bioresorbable scaffold. The Fantom scaffold, made from REVA’s advanced proprietary polymer, is designed to allow the restoration of blood flow in patients being treated for coronary artery disease, then resorb from the body over time. The FANTOM II trial will enroll patients at multiple clinical sites in eight countries. Data from up to 110 patients in this trial is intended to be used in a European CE Mark application which is expected to occur by mid-2016. The live implant of the Fantom scaffold involved a patient that presented with a 70% blockage of the left anterior descending artery of the heart. The Fantom scaffold was clearly visible during the procedure, easily delivered to the location of the blockage, and expanded to its intended diameter in a standard clinical procedure to restore blood flow.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|